Intravenous immunoglobulin products: an update on their mechanisms of action
J. W. Semple,
A. R. Crow,
A. H. Lazarus,
J. Freedman,
M. B. Garvey,
J. W. Semple
Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Departments of
Pharmacology,
Medicine and
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
Canadian Blood Services, Toronto, Ontario, Canada
The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada
Search for more papers by this authorA. R. Crow
Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Departments of
Canadian Blood Services, Toronto, Ontario, Canada
The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada
Search for more papers by this authorA. H. Lazarus
Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Departments of
Medicine and
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
Canadian Blood Services, Toronto, Ontario, Canada
The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada
Search for more papers by this authorJ. Freedman
Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Departments of
Medicine and
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
Canadian Blood Services, Toronto, Ontario, Canada
The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada
Search for more papers by this authorM. B. Garvey
Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Departments of
Medicine and
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
Canadian Blood Services, Toronto, Ontario, Canada
The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada
Search for more papers by this authorJ. W. Semple,
A. R. Crow,
A. H. Lazarus,
J. Freedman,
M. B. Garvey,
J. W. Semple
Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Departments of
Pharmacology,
Medicine and
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
Canadian Blood Services, Toronto, Ontario, Canada
The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada
Search for more papers by this authorA. R. Crow
Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Departments of
Canadian Blood Services, Toronto, Ontario, Canada
The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada
Search for more papers by this authorA. H. Lazarus
Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Departments of
Medicine and
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
Canadian Blood Services, Toronto, Ontario, Canada
The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada
Search for more papers by this authorJ. Freedman
Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Departments of
Medicine and
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
Canadian Blood Services, Toronto, Ontario, Canada
The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada
Search for more papers by this authorM. B. Garvey
Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Departments of
Medicine and
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
Canadian Blood Services, Toronto, Ontario, Canada
The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada
Search for more papers by this author
: John W. Semple, Department of Laboratory Medicine, St. Michael's Hospital, University of Toronto, 30 Bond St, Toronto, Ontario, Canada M5B 1W8E-mail: [email protected]
Conflict of Interests: All authors declare no conflict of interests.
References
- 1 Bruton OC: Agammaglobulinemia. Pediatrics 1952; 9: 722–725
- 2 Anonymous: ASHP therapeutic guidelines for intravenous immune globulin. ASHP Commission on Therapeutics. Clinical Pharmacy 1992; 11: 117–128
- 3 Fischer GW: Uses of intravenous globulin to prevent or treat infections. Adv Pediatric Infect Dis 1992; 7: 85–92
- 4 Imbach P, Barandun S, D’Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1128–1131
- 5 Macintyre EA, Linch DC, Macey MG, Newland AC: Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia. Br J Haematol 1985; 60: 387–344
- 6 Newland AC, Treleaven JG, Minchinton RM, Waters AH: High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1983; 1: 84–87
- 7 Fehr J, Hofmann V, Kappeler U: Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. New Engl J Med 1982; 306: 1254–1258
- 8 Samuelsson A, Towers TL, Ravetch JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484–486
- 9 Hansen RJ, Balthazar JP: Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 2002; 88: 898–899
- 10 Aukrust P, Froland SS, Liabakk NB, Muller F, Nordoy I, Haug C, Espevik T: Release of cytokines, soluble cytokine receptors and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84: 2136–2143
- 11 Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE: Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765–769
- 12 Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH: Intravenous immunoglobulin ameliorates ITP via activating Fcgamma receptors on dendritic cells. Nat Med 2006; 12: 688–692
- 13 Blanchette VS, Semple JW, Freedman J: Intravenous immunoglobulin and Rh immunoglobulin as immunomodulators of autoimmunity to blood elements; in LE Silberstein (ed): Autoimmune disorders of blood. Bethesda, American Association of Blood Banks, 1996: 35
- 14 Cines DB, Blanchette VS: Immune thrombocytopenic purpura. New Eng J Med 2002; 346: 995–1008
- 15 Tovo PA, Miniero R, Fiandino G, Saracco P, Messina M: Fc-depleted vs intact intravenous immunoglobulin in chronic ITP. J Pediatr 1984; 105: 676–683
- 16 Ericson SG, Coleman KD, Wardwell K, Baker SD, Fanger MW, Guyre PM, Ely P: Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. Br J Haematol 1996; 92: 718–723
- 17 Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC: Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. New Engl J Med 1986; 314: 1236–1242
- 18 Kurlander RJ, Hall J: Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986; 77: 2010–2018
- 19 Burdach SE, Evers KG, Geursen RG: Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: comparative efficacy of 7S and 5S preparations. J Pediatr 1986; 109: 770–775
- 20 Teeling JL, Jansen-Hendriks T, Kuijpers TW, De Haas M, Van De Winkel JGJ, Hack CE, Bleeker WK: Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98: 1095–2001
- 21 Crow AR, Song S, Semple JW, Freedman J, Lazarus AH: IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001; 115: 679–686
- 22 Crow AR, Song S, Freedman J, Helgason CD, Humphries RK, Siminovich KA, Lazarus AH: IVIg-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 2003; 102: 558–560
- 23 Bruhns P, Samuelsson A, Pollard JW, Ravetch JV: Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003; 18: 573–581
- 24 Simister NE, Mostov KE: An Fc receptor structurally related to MHC class I antigens. Nature 1989; 337: 184–187
- 25 Fateh-Moghadam A, Wick M, Besinger U, Geursen RG: High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984; 1: 848–849
- 26 Hammarstrom L, Abedi MR, Hassan MS, Smith CI: The SCID mouse as a model for autoimmunity. J Autoimmun 1993; 6: 667–674
- 27 Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B: High-dose intravenous immune globulin for stiff-person syndrome. New Engl J Med 2001; 345: 1870–1876
- 28 Hansen RJ, Balthazar JP: Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002; 100: 2087–2093
- 29 Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, Roopenian DC, Liu Z: Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005; 115: 3440–3450
- 30 Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister N: Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 1996; 89: 573–578
- 31 Arend WP, Leung DY: IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 1994; 139: 71–78
- 32 Arend WP, Malyak M, Guthridge CJ, Gabay C: Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16: 27–55
- 33 Iizasa H, Yoneyama H, Mukaida N, Katakoka Y, Naito M, Yoshida N, Nakashima E, Matsushima K: Exacerbation of granuloma formation in IL-1 receptor antagonist-deficient mice with impaired dendritic cell maturation associated with Th2 cytokine production. J Immunol 2005; 174: 3273–3280
- 34 Cooper N, Heddle NM, Haas M, Reid ME, Lesser ML, Fleit HB, Woloski BM, Bussel JB: Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol 2004; 124: 511–518
- 35 Crow AR, Song S, Semple JW, Freedman J, Lazarus AH: A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood 2007; 109: 155–158
- 36 Aubin E, Lemieux R, Bazin R: Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti-red blood cell antibodies in a mouse model of immune thrombocytopenic purpura. Br J Haematol 2007; 136: 837–843
- 37 Gaulton GN, Greene MI: Idiotypic Mimicry of Biological Receptors Annu Rev Immunol 1986; 4: 253–276
- 38 Berchtold P, Dale GE, Tani P, McMillan R: Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989; 74: 2414–2417
- 39 Barbano G, Saleh MN, Mori PG, LoBuglio AF, Shaw DR: Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia. Blood 1989; 73: 662–665
- 40 Debre M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, Vilmer E, Kaplan C, Teillaud JL, Griscelli C: Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342: 945–949
- 41 Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G: Dendritic cells as vectors for therapy. Cell 2001; 106: 271–274
- 42 Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV: Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101: 758–765
- 43 Kaneko Y, Nimmerjahn F, Ravetch JV: Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670–673
- 44 Tha-In T, Metselaar HJ, Tilanus HW, Groothuismink ZMA, Kuipers EJ, De Man RA, Kwekkeboom J: Intravenous immunoglobulins suppress T-cell priming by modulating the bi-directional interaction between dendritic cells and natural killer cells. Blood 2007; 110: 3253–3262
- 45 Ni H, Chen P, Spring CM, Sayeh E, Semple JW, Lazarus AH, Hynes RO, Freedman J: A novel murine model of fetal and neonatal alloimmune thrombocytopenia: Efficacy of intravenous immunoglobulin G therapy. Blood 2006; 107: 2976–2983
- 46 Kickler TS, Ness PM, Braine HG, Richardson L, Farkosh M: The expression of IgG allotypes on platelets and immunization to IgG allotypes in multitransfused thrombocytopenic patients. Blood 1990; 76: 849–855
- 47 Semple JW, Kim M, Lazarus AH, Freedman J: Gammaglobulins prepared from the sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response. Blood 2002; 100: 1055–1059
- 48 Webster ML, Sayeh E, Crow M, Chen P, Nieswandt B, Freedman J, Ni H: Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIb alpha antibodies. Blood 2006; 108: 943–946
- 49 Go RS, Johnston KL, Bruden KC: The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica 2007; 92: 283–284
- 50 Salama A, Kiefel V, Amberg R, Mueller-Eckhardt C: Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)]. Blut 1984; 49: 29–35
- 51 Kumpel BM, Elson C: Mechanism of anti-D-mediated suppression – a paradox awaiting resolution. Trends Immunol 2001; 22: 26–31
- 52 Semple JW, Allen D, Rutherford M, Wakefield C, David M, Freedman J, Wolowski M, Butchart S, Blanchette V: Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. Am J Hematol 2002; 69: 225–227
- 53 Malinowska I, Obitko-Pludowska A, Buescher ES, Wasik M, Rokicka-Milewska R: Release of cytokines and soluble cytokine receptors after intravenous anti-D treatment in children with chronic thrombocytopenic purpura. Hematol J 2001; 2: 242–249
- 54 Coopamah MD, Freedman J, Semple JW: Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. Blood 2003; 102: 2862–2867
- 55 Aslam R, Kim M, Speck ER, Seetanah AC, Molinski S, Freedman J, Semple JW: Platelet and erythrocyte phagocytosis kinetics are differentially controlled by phosphatase activity within mononuclear cells. Transfusion 2007; 47: 2161–2168
- 56 Kumpel BM, Beliard R, Brossard Y, Edelman L, De Haas M, Jackson DJ, Kooyman P, Ligthart PC, Monchatre E, Overbeeke MAM, Puillandre P, De Romeuf C, Wilkes AM: Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinators report. Transfus Clinique Biologique 2002; 9: 45–53
- 57 Godeau B, Oksenhendler E, Brossard Y, Bartholeyns J, Leaute JB, Duedari N, Schaeffer A, Bierling P: Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D. Transfusion 1996; 36: 328–330
- 58 Engelfriet CP, Reesink H: The treatment of patients with autoimmune thrombocytopenia with intravenous IgG-anti-D. Vox Sang 1999; 76: 250–255
- 59 Kjaersgaard M, Aslam R, Kim M, Speck ER, Freedman J, Stewart DI, Weirsma E, Semple JW: Epitope specificity and isotype of monoclonal anti-D antibodies dictate their ability to inhibit phagocytosis of opsonized platelets. Blood 2007; 110: 1359–1361
- 60 Song S, Crow AR, Siragam V, Freedman J, Lazarus AH: Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 2005; 105: 1546–1548
- 61 Boughton BJ, Cooke RMS, Smith N, Simpson A, Sato Y: Autoimmune thrombocytopenia: anti-glycoprotein IIb/IIIa auto antibodies are reduced after human anti-D immunoglobulin treatment. Autoimmunity 1994; 18: 141–144
